Dr Sara Tolaney highlights exploratory biomarker analyses from the phase 3 ASCENT-03 trial evaluating sacituzumab govitecan as a first-line treatment for patients with locally advanced unresectable or metastatic triple-negative breast cancer who are not candidates for PD-(L)1 inhibitors.

The discussion focuses on how sacituzumab govitecan improves progression-free survival compared with chemotherapy across multiple biomarker-defined subgroups.

The findings demonstrate consistent progression-free survival benefit with sacituzumab govitecan regardless of Trop-2 expression levels, tumour BRCA mutation status, and HER2 expression.

Clinical benefit is observed across both BRCA wild-type and mutated populations, as well as in HER2-low and HER2-zero disease, reinforcing the broad activity of this treatment.

Overall, these results support sacituzumab govitecan as an effective first-line option in this patient population, delivering clinically meaningful improvements in progression-free survival across diverse biomarker groups.